微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 35.3% | -15.79% | -6.24% | 99/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 37.65% | -11.54% | -7.89% | 97/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 40.88% | -6.12% | 8.36% | 92/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 37.73% | -26.33% | -10.01% | 97/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 41.92% | -17.97% | -1.5% | 89/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 42.56% | -21.32% | -2.25% | 89/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 43.54% | -23.69% | -14.97% | 85/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 51.21% | -14.45% | 0.2% | 78/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 51.1% | -18.05% | -5.53% | 76/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 54.1% | -16.88% | -5.2% | 70/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 57.06% | -9.08% | -4.68% | 58/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 59.86% | -7.13% | -4.01% | 55/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 62.36% | -3.89% | -4.19% | 48/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 65.08% | 3.02% | 3.7% | 42/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 62.76% | 5.84% | -2.62% | 46/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 64.45% | -4.21% | -0.66% | 50/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 64.88% | -4.28% | 2.7% | 48/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 63.17% | -4.83% | 6.53% | 51/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 59.3% | -7.08% | -11.87% | 59/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 67.29% | 6.29% | -0.73% | 48/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 67.78% | 4.12% | 2.11% | 39/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 66.38% | -0.41% | 4.02% | 44/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 63.82% | 0.91% | 0.81% | 39/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 63.31% | -16.42% | -2.76% | 53/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 65.1% | -17.03% | -2.33% | 40/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 66.65% | -16.55% | 5.4% | 37/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 63.24% | -20.5% | -16.51% | 41/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 75.74% | -9.62% | -3.46% | 25/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 78.46% | -6.71% | -1.77% | 16/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 79.87% | -5.09% | 0.41% | 16/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 79.55% | -5.12% | -5.08% | 14/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 83.8% | 12.98% | -0.36% | 16/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 84.1% | 22.25% | -0.06% | 10/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 84.15% | 34.34% | 0.38% | 11/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 83.84% | 34.45% | 13.03% | 11/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 74.17% | 19.87% | 7.82% | 21/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 68.8% | 2% | 9.83% | 19/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 62.64% | 2% | 1.23% | 26/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 61.88% | 0.14% | 0.14% | 30/159 | 48.17% | 退市金泰 | 95.93% | 行业排名> |